Top Risk Factor for Mental Disorders Identified

Early life adversity including neglect and physical, emotional, and sexual abuse is the single biggest risk factor for psychiatric disorders, new research suggests.

In what has been described as a seminal review, investigators at Dell Medical School in Austin, Texas, conclude that childhood maltreatment is “by far” the biggest contributing factor leading to impaired health in adults.

Dr. Charles Nemeroff, MD, PhD

Physically, early abuse is associated with reduced life expectancy due to higher risk for heart disease, stroke, obesity, diabetes, and certain forms of cancer, study co-author Charles Nemeroff, MD, PhD, professor and chair, department of psychiatry at Dell’s Mulva Clinic for the Neurosciences, and director of its Institute for Early Life Adversity Research, told Medscape Medical News.

In terms of the psychiatric impact, “maltreatment increases the risk for depression, drug abuse, suicide, alcohol abuse, and it also worsens the course of all psychiatric disorders that have been looked at,” Nemeroff added.

The paper was published in the January issue of the American Journal of Psychiatry.

High Rates of Maltreatment an Underestimate?

Shockingly, estimates show that about one in four children will experience abuse or neglect, although this might well be an underestimate as most cases of maltreatment go unreported.

“This is especially true for certain types of childhood maltreatment (notably emotional abuse and neglect), which may never come to clinical attention but have devastating consequences on health independently of physical abuse and neglect or sexual abuse,” Nemeroff and co-author Elizabeth Lippard, PhD, write.

Pointing to a recent meta-analysis showing that 46% of patients with depression experienced childhood maltreatment, the authors also note that up to 57% of patients with bipolar disorder also report high levels of childhood abuse and/or neglect.

The research also suggests childhood maltreatment is associated with poor treatment outcomes in patients with depression, post-traumatic stress disorder (PTSD), or bipolar disorder.

These findings underscore the need for clinicians to conduct detailed evaluations of trauma history, said Nemeroff.

“It’s extremely important for clinicians to get a detailed childhood trauma history of a patient so they know what they’re dealing with. Many patients don’t volunteer information, particularly during the first visit, about whether they have had any adverse early childhood experiences,” he said.

“We need to try to understand how best to treat these patients because they don’t respond well to conventional treatments — medication or psychotherapies,” said Nemeroff.

Evolving research is examining the timing, duration, and severity of childhood maltreatment. Some studies suggest maltreatment earlier in life that continues for a longer period is associated with worse outcomes. However, the authors emphasize that exposure to maltreatment at any time during childhood significantly increases the risk for mood disorders.

The review also includes studies of the negative consequences of bullying. While there’s some evidence to indicate that cyberbullying often precipitates suicide and that this appears to occur more often with women than men, said Nemeroff, much of the data in this area is “anecdotal.”

Most Prevalent, Least Studied

With respect to subtypes of childhood maltreatment, the authors note that emotional abuse and neglect are likely the most prevalent in psychiatric populations, but are the least studied.

In part, this is because patients who experience these types of abuse are often the least likely to come to clinical attention compared with those with physical and sexual abuse, which often results in physical injury.

“In many studies, but not all, neglect has the most devastating consequences in terms of mood and anxiety disorders,” said Nemeroff. However, he added, few individuals suffer a single isolated type of abuse.

“Very often, they’re victims of mixed forms of abuse like physical and sexual abuse, and emotional abuse.”

Emerging evidence suggests childhood maltreatment may increase the risk for mood disorders and disease progression via inflammation, as indicated by measures such as C-reactive protein (CRP) and inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6.

Anti-inflammatory medications are a promising novel therapeutic strategy in depressed patients with elevated inflammatory markers. However, this evidence is still preliminary, the authors note.

Another potential mechanism is through alterations of the hypothalamic-pituitary-adrenal axis and corticotropin-releasing factor (CRF) circuits that regulate endocrine, behavioral, immune, and autonomic responses to stress.

Genetic predisposition also likely plays a role in the pathogenesis of mood disorders following early life stress. Only 35% to 40% of individuals exposed to traumatic events will develop PTSD, said Nemeroff. “That’s probably largely determined by genetics.”

He estimated there might be a dozen or so genes, each of which provides a small degree of vulnerability to psychiatric disorders after exposure to trauma.

Intergenerational Genetic Trauma

The authors also point to novel research pertaining to the complex area of intergenerational transmission of trauma and psychopathology — a phenomenon that has been studied in Holocaust victims.

“It turns out that when an individual is traumatized, their ova, in the case of women, and sperm cells, in the case of men, can be changed by epigenetic mechanisms,” said Nemeroff. “In that way, the child that’s a product of these gametes can carry with it an effect of previous generations’ trauma.”

Research also suggests that childhood maltreatment may lead to structural and functional brain imaging changes. Some evidence has linked early abuse with lower gray matter volumes and thickness in the ventral and dorsal prefrontal cortex, including the orbitofrontal and anterior cingulate cortices, hippocampus, insula, and striatum.

Studies that are more recent also suggest an association with decreased white matter structural integrity within and between these regions.

“Different types of abuse and neglect result in different brain changes. It probably depends in part on how old the child is at time of the insult,” said Nemeroff.

Researchers are gaining ground in understanding why not all people exposed to childhood trauma develop a mood disorder. Environmental factors, as well as genes, may mediate the relationship between childhood abuse and mood disorders, the review authors note.

Studies also show that social support and secure attachments can buffer depression risk.

Nemeroff believes there are three critical areas for further research. These include determining whether brain and body changes that occur because of childhood abuse and neglect are reversible. In addition, he said, there needs to be more research into optimal treatments for this patient population and better methods of identifying those at risk of early adversity.

“It won’t be long before genome-wide scanning will become part of the electronic medical record,” said Nemeroff. “We screen for genetic diseases all the time in other areas; why wouldn’t we do it for this?”

In addition, when at-risk patients are identified, interventions could focus on the family unit, single parents, families living in poverty, and parents working two jobs, said Nemeroff.

Educating guidance counselors, teachers, and nurses, is also important, he said, but it is also critically important to educate clinicians about how to conduct proper evaluations.

Strengths, Limitations

Commenting for Medscape Medical News, David Fassler, MD, clinical professor of psychiatry, Larner College of Medicine, University of Vermont, Burlington, described the review as “comprehensive.”

The authors “demonstrate that the available research consistently supports the finding that childhood maltreatment increases the risk of mood disorders,” said Fassler.

“They also appropriately address the limitations of their review, including varying definitions of maltreatment and the use of different assessment instruments across studies,” he said.

Given the prevalence of childhood maltreatment, the review “further underscores the importance of comprehensive initiatives designed to protect young people from such traumatic and harmful experiences. Hopefully, the findings will also inform future research on the treatment and prevention of adult mood disorders,” Fassler said.

Source : Medscape

FDA Approves Tazemetostat, First Drug for Epitheloid Sarcoma

For the first time, a drug has been approved by the US Food and Drug Administration (FDA) for the treatment of epithelioid sarcoma, a rare subtype of soft tissue sarcoma that occurs in young adults.

The drug is tazemetostat (Tazverik, Epizyme Inc), and it acts as an inhibitor of EZH2 methyltransferase. It is indicated for the treatment of metastatic or locally advanced epithelial sarcoma in cases in which complete resection is not possible.

This is the first drug with that mechanism of action, and it is the first to be indicated for epithelioid sarcoma, the agency noted.

The FDA granted an accelerated approval on the basis of response rate data from an open-label clinical trial in 62 patients. All patients received tazemetostate 800 mg twice daily. The overall response rate was 15% (9 of 62 patients), with 1.6% of patients having a complete response and 13% having a partial response. Among the nine patients who had a response, six (67%) patients had a response that lasted 6 months or longer.

The most common side effects were pain, fatigue, nausea, decreased appetite, vomiting, and constipation. Tazemetostate may increase the risk for secondary malignancies, the agency noted.

When these data were discussed at a recent meeting of the FDA’s Oncologic Drugs Advisory Committee, “the committee voted unanimously that the benefits of the drug outweighed the risks,” commented Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence.

“Until today, there were no treatment options specifically for patients with epithelioid sarcoma,” he added. This approval “provides a treatment option that specifically targets this disease.”

Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial. The manufacturer is now conducting a global, randomized, controlled confirmatory trial to assess the combination of tazemetostat plus doxorubicin compared with doxorubicin plus placebo as a frontline treatment for epithelial sarcoma.

Rare Tumor, Often Metastatic on Diagnosis

Epithelioid sarcoma is rare. It accounts for fewer than 1% of all sarcomas and is diagnosed in 150 to 200 people in the United States each year.

The diagnosis can be easily missed. The disease often presents as a hard lump in soft tissue, such as under the skin in the extremities or in the abdomen or groin, in young adults (aged 20–30 years) who are apparently healthy.

Surgery is usually considered if the tumor is localized in one part of the body. Chemotherapy and radiotherapy may also be given, the FDA notes. However, there is a high likelihood of local and regional spread of the disease even with treatment, and approximately 50% of patients have metastatic disease at the time of diagnosis. Metastatic disease is considered life-threatening, the agency notes.

“There are limited therapeutic options for treating patients with epithelioid sarcoma, who struggle with high rates of recurrence and toxicities associated with currently used therapies,” said Gary K. Schwartz, MD, chief of hematology and oncology at Columbia University and New York–Presbyterian Hospital, New York City. He was the lead investigator of the clinical trial of tazemetostat.

The results from that trial “support its potential to provide clinically meaningful and durable responses, and tolerability,” he said in a statement.

“For people with epithelioid sarcoma, an aggressive life-threatening cancer that affects young adults, having new treatment options can offer much needed hope,” added Denise Reinke, MS, NP, MBA, president and chief executive officer of the Sarcoma Alliance for Research Through Collaboration (SARC) and cofounder of the Sarcoma Coalition.

Source : Medscape

Low-Dose CT Reduces Radiation Exposure Without Missing Injuries in Trauma Patients

In blunt trauma patients, low-dose whole body computed tomography (WBCT) does not seem to increase the risk of missed injury diagnoses compared with standard-dose protocols, and almost halves exposure to diagnostic radiation, a quasi-experimental study suggests.

“In suspected multiple trauma, radiological imaging…plays an integral role during initial work-up and resuscitation,” Dr. Dirk Stengel of BG Kliniken-Klinikverbund der Gesetzlichen Unfallversicherung gGmbH in Berlin told Reuters Health by email. “In industrialized countries and at designated trauma centers, an early WBCT scan from the skull to the pelvis – often coined the ‘pan-scan’ – emerged as a preferred option to screen for life-threatening injuries.”

“As many patients are rather young,” he said, “excess radiation with a liberal pan-scan policy remains an issue of debate.”

Several imaging approaches for reducing noise and radiation in CT technology are available from major manufacturers of high-end multisclice scanners, he noted. “No previous large-scale study had investigated the clinical effects – i.e., rate of missed injuries, diagnostic accuracy – of lowering the radiation dose to the currently achievable minimum.”

Dr. Stengel and colleagues recruited 565 consecutive patients admitted for suspected blunt multiple trauma from September 2014 through July 2015 for the standard-dose protocol, and 509 patients from August 2015 through August 2016 for the low-dose protocol.

As reported in JAMA Surgery, 971 patients (mean age, 52.7; 66.8% men) completed the study. One hundred and fourteen (11.7%) had multiple trauma, defined as an Injury Severity Score of 16 or greater.

A missed injury diagnosis at the point of care was defined as any injury demanding clinical awareness or therapeutic action at any time, but that was not recognized in the initial WBCT or contained in the initial (“hot”) report provided to the trauma team.

The proportion of patients with any such injury was 23.3% in the standard-dose and 21.3% in the low-dose WBCT groups (unadjusted odds ratio, 0.89). Adjustments for autocorrelation and multiple confounding variables did not alter the results.

Radiation exposure, measured by the volume CT dose index, was lowered from a median of 11.7 mGy in the standard-dose group to 5.9 mGy in the low-dose group. The median dose-length product was reduced from 1,109 mGy/cm to 735 mGy/cm.

Further, the contrast-to-noise ratio consistently favored low-dose WBCT for all investigated anatomical regions.

Dr. Stengel said, “We conclude that, if WBCT scanning is considered the diagnostic strategy of choice, it should be performed at low-dose using a modern iterative image-processing algorithm.”

With that said, based on a 2012 report from the same team (http://bit.ly/2Gi4Mob), “we stress that an initially ‘negative’ WBCT scan is not confirmative,” he added. “Certain injuries in trauma patients simply need time to demark. In the early phase of resuscitation, patients may have a centralized circulatory system, and active bleeding to the large body cavities – i.e., cranium, thorax, abdomen, retroperitoneum, pelvis – can only be detected after volume has been replaced.”

“We urge trauma teams worldwide to find the appropriate balance amongst the ideal time of scheduling patients to a WBCT scan and its capability to detect injuries,” he concluded.

Dr. Anthony Charles of the University of North Carolina at Chapel Hill, coauthor of a related editorial, noted in an email to Reuters Health that although it was a good study, he has concerns.

“In trauma, there is acuity, and the risk of missed injury is much higher than a very low potential risk of radiation-induced cancer in the future,” he said. “In addition, this study had a high baseline risk of missed injury within the regular and low-dose WBCT groups – certainly, a lot higher missed injury rate than we see in the United States.”

“If they had missed injury rates similar to the U.S., this study would have shown that low-dose WBCT resulted in a higher missed injury rate,” he said.

“The strength of any radiologic study is in the image quality and the interpretation,” he added. “Radiologists as well as trauma surgeons (who also must concur with the radiologist interpretations of any image) must be confident that low-dose WBCT can yield the same results. This will take time and practice, but more importantly, more robust studies before one can allow low-dose WBCT to go mainstream.”

Source : Medscape

Titrated Doses of Enoxaparin Better Prevent VTE After Cancer Surgery

Adjusting the doses of enoxaparin based on anti-Xa levels, instead of using standard doses, may better prevent venous thromboembolism (VTE) without worsening bleeding rates in patients undergoing abdominal cancer surgery, according to a new study.

“What we found most surprising is that majority of patients who underwent cancer surgery were found to have inadequate doses of deep-vein thrombosis (DVT) prophylaxis (enoxaparin) based on current recommended guidelines,” said Dr. Gitonga Munene of Western Michigan University Homer Stryker MD school of medicine, in Kalamazoo, Michigan.

“This indicates that we may not be reducing the risk of DVT and pulmonary embolism (PE) in the majority of cancer-surgery patients if we continue using the current recommended doses,” he told Reuters Health by email.

Patients with cancer already have an increased risk of VTE, and cancer surgery further elevates that risk. The presence of VTE after major cancer surgery has been associated with a five-fold increase in the risk of mortality. Enoxaparin, a low-molecular-weight heparin, is widely used to prevent VTE after cancer surgery.

Dr. Munene’s team examined the efficacy and safety of dose-adjusted enoxaparin guided by anti-Xa levels in 64 prospectively enrolled patients undergoing abdominal cancer surgery versus recommended thromboprophylaxis doses (unfractionated heparin 5000 U three times daily or enoxaparin 40 mg once daily) in a historical control group of 133 similar patients.

Patients in the intervention group had initial enoxaparin doses of 40 mg once daily. If their initial anti-Xa level was below 0.2 IU/mL, the dose was increased to 30 mg twice daily, and subsequent doses were increased by 10 mg per dose until serum anti-Xa levels were between 0.2 and 0.4 IU/mL, the maximum dose of enoxaparin 60 mg twice daily was reached, or the patient was discharged from the hospital.

None of the patients in the intervention group developed VTE, whereas 11 patients (8%, P=0.018) in the control group developed VTE, including six patients (11%) receiving enoxaparin and five (7%) receiving heparin.

The groups did not differ significantly in major bleeding events, postoperative transfusion requirements, or mean discharge hemoglobin levels, the researchers report in the Journal of the American College of Surgeons.

In the intervention arm, only 14 of 64 patients (22%) achieved an initial prophylactic anti-Xa level of at least 0.2 IU/mL. Overall, 23 patients required one adjustment in enoxaparin dosing, and 12 patients required two adjustments in enoxaparin dosing.

Seven patients remained subprophylactic after two adjustments but did not remain hospitalized long enough to have a fourth anti-Xa level drawn.

Patients with doses that were initially subprophylactic were significantly younger, had a higher BMI and a longer operative time than did patients with initially prophylactic doses of enoxaparin.

“Current guidelines for DVT thromboprophylaxis in cancer surgery and trauma surgery (published data by another group) and other high-risk surgeries may need to be revised to reflect the use of anti-Xa levels in determining correct dosage of enoxaparin,” Dr. Munene said. “Additional randomized trials would need to be conducted to document and confirm the efficacy and safety of this approach in cancer patients and other surgery patients.”

Dr. Taishi Hata from Kansai Rosai Hospital, in Amagasaki, Japan, and colleagues recently reported that anticoagulant prophylaxis with enoxaparin or fondaparinux did not significantly reduce the incidence of VTE following laparoscopic colorectal cancer surgery. He told Reuters Health by email, “Cancer patients are VTE high risk, and they may need more doses of enoxaparin than non-cancer patients.”

“The recommended dose of enoxaparin by guideline may be too low for cancer patients,” said Dr. Hata, who was not involved in the new work.

Source : Medscape

Tailored Pelvic PT May Curb Post-Prostatectomy Stress Incontinence, Pain

After prostate surgery, individualized pelvic physical therapy to relax or strengthen the pelvic muscles may be more effective for reducing stress urinary incontinence (SUI) and pelvic pain than muscle strengthening alone, researchers suggest.

“Our findings suggest that we are doing a disservice to many patients with post-prostatectomy urinary incontinence by merely teaching them pelvic floor muscle exercises,” urologist Dr. Gary Lemack of UT Southwestern Medical Center in Dallas told Reuters Health by email. “At the very least, if these exercises are unsuccessful, then referral to a comprehensive pelvic floor program for a more patient-specific approach is recommended to enhance recovery of bladder function.”

The study was a retrospective chart review of 136 patients (mean age, 66) with post-prostatectomy SUI treated with pelvic physical therapy: 25 had underactive pelvic floor dysfunction (PFD) requiring only uptraining (strengthening) treatment; 13 had only overactive dysfunction and were treated with downtraining (relaxation); and 98 had mixed-type PFD with components of both underactivity and overactivity, and were treated with both uptraining and downtraining.

As reported in International Urology and Nephrology, those with uptraining, as well as those with downtraining, showed significant improvement in the number of pads used per day; decreased pelvic pain on a numeric pain rating scale; and increased pelvic floor strength – even for those who mainly received relaxation training to normalize pelvic floor overactivity.

Specifically, overall, there was a mean decrease in the initial resting tone while side-laying, as determined by biofeedback, from 3.30 to 2.30, and an increase in maximal contraction strength in the side-laying position from 22.49 to 28.97.

The mean pain score decreased with treatment from 0.88 to 0.30. Further, 79% of patients were compliant with all treatment recommendations.

Summing up, the authors state, “a majority of post-prostatectomy men with SUI have pelvic floor overactivity in addition to pelvic floor underactivity. An individualized pelvic PT program aimed at normalizing pelvic floor function (as opposed to a pure Kegel strengthening program) can be helpful in reducing SUI and pelvic pain.”

Dr. Lemack said, “Improvements in the surgical treatment of prostate cancer have improved post-operative recovery substantially but have not eliminated the risk of urinary incontinence. Appropriate diagnosis and management of pelvic floor dysfunction in the post-operative setting by properly trained specialists in pelvic floor disorders may obviate the need for additional, potentially more morbid, invasive procedures.”

Dr. Andrew Albright, a physical therapist at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, told Reuters Health, “I am not surprised by and do agree with the findings. From what I have seen within this specific patient population, performing strengthening exercises (Kegels) with an overactive and guarded pelvic floor can actually be counterproductive.”

 

“With most surgeries, the immediate and surrounding regions can become weak, but these local and adjacent regions also can become guarded and overactive, leading to further dysfunction,” he said by email. “We need to treat and correct these dysfunctions to (restore) optimal function to improve the quality of lives of our patients.”

 

“This was a retrospective review of data,” he added. “It would definitely be beneficial to have randomized, controlled trials in the future.”

Source : Medscape